Table 1.
Potentiation assessment of lead polyamine compounds.
| MW | EPI∗a | TET+EPI∗b | FP∗c | TET+EPI#b | FP#c | |
|---|---|---|---|---|---|---|
| 247 | 368.56 | >25 | 9 | 5.0 | 12 | 8.3 |
| 250 | 340.51 | >25 | 9 | 7.0 | 12 | 7.8 |
| 266 | 368.56 | >25 | 9 | 6.8 | 16 | 5.8 |
| 271 | 354.53 | >25 | 5 | 8.2 | 10 | 8.5 |
| 314 | 354.53 | >25 | 9 | 5.0 | 12 | 7.5 |
| Reserpine | 608.68 | >25 | 4 | 11.2 | >50 | 1 |
| PAβN | 519.47 | >25 | 0.7 | 65.5 | 11.63 | 8 |
All assays were performed in triplicate alongside no drug controls, known efflux pump inhibitors (EPIs) reserpine and PAβN, and tetracycline alone controls (data not shown due to repetitive values, average concentration for EC50 across all replicates = 47.8 μM; EC90 = 82.5 μM). Molecular weight (MW) of all compounds is displayed as grams mole-1. ∗50% effective concentrations (EC50). #90% effective concentrations (EC90). aEPI is the inhibitory concentration of the individual Efflux Pump Inhibitor (EPI) alone (μg mL-1).bTET+EPI is the respective EC tetracycline (μM) in the presence of each compound. cFP is Fold Potentiation = EC tetracycline + EPI/EC tetracycline (no EPI).